Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2020 16:20 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call

LA JOLLA, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune...
April 28, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020

LA JOLLA, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune...
April 23, 2020 09:00 ET | Source: INmune Bio, Inc.

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer

Neutralization of Soluble TNF may decrease progression of breast cancerand lessen resistance to breast cancer immunotherapy LA JOLLA, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc....
April 22, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells

LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune...
April 20, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19

Conference call at 4:15 PM ET with management to discuss the science and strategy of clinical trial to determine if the Company’s DN-TNF platform could be used to treat catastrophic complications of...
March 11, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH

LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to...
March 05, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17

LA JOLLA, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced...
February 27, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results

LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat disease, today...
February 10, 2020 09:08 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS

Grant will fund proof-of-concept studies for XPro1595 therapy LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments...
January 02, 2020 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

LA JOLLA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease,...